Risultati per: Identificata la causa della progressione dell’Alzheimer nel cervello

This cohort study investigates the association of changes in levels of plasma tau phosphorylated at threonine 181 and neurofilament light chain protein with psychotic symptoms in Alzheimer disease.

Un nuovo studio suggerisce che il primo farmaco Glp-1 impiegato per combattere diabete e obesità, può ridurre la perdita di massa cerebrale

Lo conferma uno studio su 1.200 persone

This Medical News article is an interview with retired neurologist Daniel Gibbs, who is living with Alzheimer disease.

Corteccia cerebrale più sottile e permeabilità dell’intestino

Dieta equilibrata e attività fisica possono prevenire malattie

Apre nuove prospettive contro l’osteoporosi

Almost all people who inherited 2 identical copies of the APOE4 gene variant had abnormally high levels of amyloid in their cerebrospinal fluid and brain by age 65 years, according to a new study that combined data from more than 3200 brain donors and about 10 000 participants with clinical data.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Volume 390, Issue 23, Page 2217-2219, June 20, 2024.

New England Journal of Medicine, Volume 390, Issue 23, Page 2156-2164, June 20, 2024.

New England Journal of Medicine, Volume 390, Issue 23, Page 2212-2213, June 20, 2024.

This Viewpoint discusses how data gaps in published research impede clinicians’ ability to clearly discuss the risks and benefits of amyloid-lowering drugs for treating Alzheimer disease.

I consulenti dell’Fda hanno approvato il farmaco di Eli Lilly. Entro la fine dell’anno si attende l’ok definitivo da parte dell’Ente regolatorio